摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5'-(4-amino-2-oxa)butyl-4,4',8-trimethylpsoralen | 161262-42-6

中文名称
——
中文别名
——
英文名称
5'-(4-amino-2-oxa)butyl-4,4',8-trimethylpsoralen
英文别名
2-(2-Aminoethoxymethyl)-3,5,9-trimethylfuro[3,2-g]chromen-7-one
5'-(4-amino-2-oxa)butyl-4,4',8-trimethylpsoralen化学式
CAS
161262-42-6
化学式
C17H19NO4
mdl
——
分子量
301.342
InChiKey
UITNHEZFROQNSX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    74.7
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Method for inactivating pathogens in blood using photoactivation of
    摘要:
    合成了带有取代基的苯麻酚化合物,这些取代基位于苯麻酚的4、4'、5'和8位,使其能够更好地结合病原体的核酸。描述了更高的苯麻酚结合水平和更低的致突变性,从而在血液制品中更安全、更高效、更可靠地灭活病原体。该发明考虑了使用新苯麻酚进行灭活的方法,这些方法不会损害用于输血的血液制品的功能。
    公开号:
    US05593823A1
点击查看最新优质反应信息

文献信息

  • Method and devices for the removal of psoralens from blood products
    申请人:——
    公开号:US20020115585A1
    公开(公告)日:2002-08-22
    Method for removing a pathogen-inactivating compound such as psoralen from a biological fluid such as blood or a blood product. One such method involves treating a blood product which contains a nucleic acid-containing pathogen to be inactivated. This method includes adding a pathogen-inactivating compound such as psoralen to the blood product; irradiating the psoralen and the blood product to form a mixture comprising the blood product, free psoralen, and low molecular weight psoralen photoproducts; and contacting the mixture with a hypercrosslinked resin to remove at least substantially all of the free psoralen and the low molecular weight psoralen photoproducts. A hypercrosslinked resin in this method preferably eliminates a wetting step that a number of other types of resins require before being used to adsorb the pathogen inactivating compound.
    从生物液体(如血液或血液制品)中去除一种病原体灭活化合物(如紫荆素)的方法。其中一种方法涉及处理含有核酸病原体的血液制品以进行灭活。该方法包括向血液制品中添加病原体灭活化合物(如紫荆素);照射紫荆素和血液制品以形成含有血液制品、游离紫荆素和低分子量紫荆素光产物的混合物;并将该混合物与超交联树脂接触,以去除至少几乎所有的游离紫荆素和低分子量紫荆素光产物。在该方法中,超交联树脂优选地消除了其他类型的树脂在用于吸附病原体灭活化合物之前需要进行的浸润步骤。
  • Method for inactivating pathogens in blood using photoactivation of
    申请人:Cerus Corporation
    公开号:US05593823A1
    公开(公告)日:1997-01-14
    Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
    合成了带有取代基的苯麻酚化合物,这些取代基位于苯麻酚的4、4'、5'和8位,使其能够更好地结合病原体的核酸。描述了更高的苯麻酚结合水平和更低的致突变性,从而在血液制品中更安全、更高效、更可靠地灭活病原体。该发明考虑了使用新苯麻酚进行灭活的方法,这些方法不会损害用于输血的血液制品的功能。
  • BATCH DEVICES FOR THE REDUCTION OF COMPOUNDS FROM BIOLOGICAL COMPOSITIONS CONTAINING CELLS AND METHODS OF USE
    申请人:——
    公开号:US20010018179A1
    公开(公告)日:2001-08-30
    Methods and devices are provided for reducing the concentration of low molecular weight compounds in a biological composition containing cells while substantially maintaining a desired biological activity of the biological composition. The device comprises highly porous adsorbent particles, and the adsorbent particles are immobilized by an inert matrix.
    提供了一种方法和装置,用于在基于细胞的生物组成物中减少低分子量化合物的浓度,同时基本维持所需的生物活性。该装置包括高度多孔吸附剂颗粒,并且这些吸附剂颗粒被惰性基质固定。
  • [EN] COMPOUNDS FOR THE PHOTODECONTAMINATION OF PATHOGENS IN BLOOD<br/>[FR] COMPOSES SERVANT A LA PHOTODECONTAMINATION D'AGENTS PATHOGENES DANS LE SANG
    申请人:CERUS CORPORATION
    公开号:WO1996014739A1
    公开(公告)日:1996-05-23
    (EN) Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for tranfusion.(FR) Synthèse de composés de psoralène présentant des substitutions au niveau des positions 4, 4', 5', et 8 qui en permettent la fixation améliorée à l'acide nucléique d'agents pathogènes. L'augmentation des niveaux de fixation du psoralène et la réduction de la mutagénicité décrites permettent une inactivation plus sûre, plus efficace et plus fiable des agents pathogènes présents dans les produits sanguins. L'invention porte également sur des méthodes d'inactivation à l'aide desdits nouveaux psoralènes ne compromettant pas la fonction des produits sanguins destinés à la transfusion.
    (psoralen化合物被合成,其在psoralen的4、4'、5'和8位置上有取代基,从而增强了与病原体核酸的结合。描述了更高的psoralen结合水平和更低的致突变性,从而在血液制品中实现更安全、更有效和可靠的病原体灭活。本发明考虑使用新的psoralen进行灭活方法,不会影响输血用血液制品的功能。)
  • Absorbents and devices for the reduction of small organic compounds from blood products
    申请人:Cerus Corporation
    公开号:EP1508345A1
    公开(公告)日:2005-02-23
    The present invention relates to a system for use in treating a blood product containing a pathogen inactivating agent comprising a biocompatible housing and an adsorbent medium having (1) adsorbent resin particles capable of adsorbing the pathogen inactivating agent, and (2) an inert matrix in which the adsorbent resin particles are immobilized; wherein the immobilized adsorbent particles have a diameter from about 100 µm to about 1200 µm when the system is configured as a batch apparatus, and the immobilized adsorbent particles have a diameter from about 1 µm to about 200 µm when the system is configured as a flow-through apparatus; and wherein said blood product substantially maintains a desired biological activity after treatment with said system.
    本发明涉及一种用于处理含有病原体灭活剂的血液制品的系统,该系统包括生物相容性外壳和吸附介质,吸附介质具有(1)能够吸附病原体灭活剂的吸附树脂颗粒,和(2)固定吸附树脂颗粒的惰性基质;其中,当系统配置为间歇式装置时,固定吸附剂颗粒的直径约为 100 µm 至约 1200 µm,而当系统配置为流动式装置时,固定吸附剂颗粒的直径约为 1 µm 至约 200 µm;并且,在使用所述系统处理后,所述血液制品基本上保持了所需的生物活性。
查看更多